Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HaptoGuard, Inc.
Published data supports gene linkage to vascular disease in diabetes
August 10th, 2005
HaptoGuard, Inc., announced publication of the first data that demonstrate broad applicability of a new animal model for drug development based on the haptoglobin gene. Haptoglobin (Hp), an antioxidant protein secreted by the liver, scavenges hemoglobin released by red blood cells and inhibits hemoglobin-induced oxidative reactions associated with inflammation, as seen in diabetic vascular disease. The new research conducted by Dr. Andrew Levy, a member of the Rappaport Family Institute for Research in the Medical Sciences at the Technion, shows that an animal model designed to express a form of haptoglobin (Hp 2) leads to greater vascular damage in...
Source: Biotech Week (2005-08-10)
|
